Accelerated water-bath thawing, completed in about 25 minutes, may help streamline clinical workflows and support efficient patient management Label update includes data showing that product stability is maintained with the 25-minute, 25° C water-bath method Label update reinforces Ferring’s commitment to improving patient and provider experience through continued innovation in the delivery and handling of ADSTILADRIN

Nadofaragene firadenovec-vncg received an NCCN Category 2A recommendation for patients with papillary tumors (+Ta/T1) without carcinoma in situ (CIS), an upgrade from its 2B recommendation Nadofaragene firadenovec-vncg maintained its Category 2A recommendation for patients with CIS with or without papillary tumors (+Ta/T1)

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in situ with or without papillary tumors (±Ta/T1)